Company: MLTX
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001821586-25-000018
Chunk: 78

Company: MoonLake Immunotherapeutics
Filing Date: 2025-08-05
Form: 10-Q
Item: Part II, Item 5
Chunk 78
---
Item 5. Other Information

Trading Arrangements

On June 17, 2025, Dr. Jorge Santos da Silva, the Chief Executive Officer and a director of the Company, adopted a trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c). Dr. Santos da Silva's plan provides for the sale, subject to certain conditions, of up to 200,000 Class A Ordinary Shares through November 24, 2025. 

48

MoonLake Immunotherapeutics

On June 17, 2025, Mr. Matthias Bodenstedt, the Chief Financial Officer of the Company, adopted a trading plan intended to satisfy the affirmative defense of Rule 10b-1(c). Dr. Bodenstedt's plan provides for the sale, subject to certain conditions, of up to 300,000 Class A Ordinary Shares through March 31, 2026.

On June 26, 2025, Dr. Kristian Reich, Chief Scientific Officer of the Company, adopted a trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c). Dr. Reich’s plan provides for the sale, subject to certain conditions, of up to 300,000 Class A Ordinary Shares through March 31, 2026.

During the three months ended June 30, 2025, no other director or Section 16 officer of the Company adopted or terminated any "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as each term is defined in Item 408(a) of Regulation S-K.

49